Veliparib

Generic Name: Veliparib

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₆N_₄O

CAS Number: 912444-00-9

Unique Ingredient Identifier: 01O4K0631N

Indication: 与化疗药物紫杉醇和卡铂联合用于治疗乳腺癌。

Clinical Trials

Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Phase 1

Completed

Conditions: Ovarian Clear Cell Cystadenocarcinoma
Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma
Ovarian Endometrioid Adenocarcinoma
Ovarian Serous Cystadenocarcinoma
Ovarian Seromucinous Carcinoma
Recurrent Primary Peritoneal Carcinoma
Undifferentiated Ovarian Carcinoma

Interventions: Biological: Bevacizumab
Drug: Carboplatin
Other: Laboratory Biomarker Analysis
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Drug: Veliparib

First Posted Date: 2011-10-25

Last Posted Date: 2019-07-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 41

Registration Number: NCT01459380

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸
Augusta University Medical Center, Augusta, Georgia, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States

and more 10 locations

ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer

Phase 1

Completed

Conditions: Neoplasms
Lymphoma

First Posted Date: 2011-10-03

Last Posted Date: 2019-12-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT01445522

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States

Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Advanced Malignant Solid Neoplasm

Interventions: Drug: Dinaciclib
Drug: Veliparib

First Posted Date: 2011-09-14

Last Posted Date: 2025-02-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 121

Registration Number: NCT01434316

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems

Phase 1

Withdrawn

Conditions: Neoplasms

First Posted Date: 2011-08-18

Last Posted Date: 2017-07-02

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT01419548

Locations: 🇺🇸
University of Pittsburgh Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Phase 1

Active, not recruiting

Conditions: Lung Adenocarcinoma, Mixed Subtype
Minimally Invasive Lung Adenocarcinoma
Lung Adenocarcinoma
Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Lung Large Cell Carcinoma
Lung Squamous Cell Carcinoma
Stage III Lung Non-Small Cell Cancer AJCC v7
Stage IIIB Lung Non-Small Cell Cancer AJCC v7

Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy
Drug: Carboplatin
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Drug: Veliparib
Other: Placebo Administration

First Posted Date: 2011-07-01

Last Posted Date: 2025-04-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 53

Registration Number: NCT01386385

Locations: 🇺🇸
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸
Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
🇺🇸
Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States

and more 231 locations

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

Phase 1

Active, not recruiting

Conditions: Ovarian Carcinoma
Unresectable Malignant Neoplasm
Endometrial Carcinoma
Melanoma
Breast Carcinoma
Malignant Head and Neck Neoplasm
Malignant Testicular Neoplasm
Metastatic Malignant Solid Neoplasm
Renal Failure
Esophageal Carcinoma

Interventions: Drug: Carboplatin
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Other: Pharmacological Study
Drug: Veliparib

First Posted Date: 2011-06-03

Last Posted Date: 2025-03-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 94

Registration Number: NCT01366144

Locations: 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

and more 14 locations

Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Phase 1

Active, not recruiting

Conditions: Stage IIIC Breast Cancer AJCC v7
Recurrent Breast Carcinoma
Stage IIIB Breast Cancer AJCC v7
Locally Advanced Unresectable Breast Carcinoma
Metastatic Breast Carcinoma
Stage IV Breast Cancer AJCC v6 and v7

Interventions: Drug: Cyclophosphamide
Other: Laboratory Biomarker Analysis
Drug: Veliparib

First Posted Date: 2011-05-11

Last Posted Date: 2025-03-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT01351909

Locations: 🇺🇸
Montefiore Medical Center-Einstein Campus, Bronx, New York, United States
🇺🇸
Montefiore Medical Center-Weiler Hospital, Bronx, New York, United States
🇺🇸
Montefiore Medical Center - Moses Campus, Bronx, New York, United States

and more 2 locations

Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors

Phase 1

Completed

Conditions: Anaplastic Large Cell Lymphoma
Chronic Lymphocytic Leukemia
Adult B Acute Lymphoblastic Leukemia
Adult Nasal Type Extranodal NK/T-Cell Lymphoma
Adult Solid Neoplasm
Lymphomatous Involvement of Non-Cutaneous Extranodal Site
Recurrent Adult Acute Lymphoblastic Leukemia
Recurrent Adult Hodgkin Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Angioimmunoblastic T-Cell Lymphoma

Interventions: Drug: Bendamustine Hydrochloride
Other: Pharmacological Study
Biological: Rituximab
Drug: Veliparib

First Posted Date: 2011-03-31

Last Posted Date: 2019-12-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 43

Registration Number: NCT01326702

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Phase II ABT-888 With Cyclophosphamide

Phase 2

Completed

Conditions: Ovarian Cancer
Primary Peritoneal Cancer
Serous Carcinoma Cancer
Triple-Negative Breast Cancer
Fallopian Tube Cancer

Interventions: Drug: ABT-888
Drug: Cyclophosphamide

First Posted Date: 2011-03-01

Last Posted Date: 2017-04-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 124

Registration Number: NCT01306032

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
🇺🇸
Mayo Clinic, Rochester, Rochester, Minnesota, United States

and more 7 locations

Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer

Phase 1

Terminated

Conditions: Advanced Adult Primary Liver Cancer
Localized Unresectable Adult Primary Liver Cancer
Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
Regional Transitional Cell Cancer of the Renal Pelvis and Ureter
Stage III Bladder Cancer
Stage III Pancreatic Cancer
Stage IIIA Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Stage IV Bladder Cancer
Stage IV Non-small Cell Lung Cancer

Interventions: Drug: gemcitabine hydrochloride
Drug: veliparib
Other: diagnostic laboratory biomarker analysis
Other: pharmacological study
Drug: cisplatin

First Posted Date: 2011-01-25

Last Posted Date: 2013-07-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 44

Registration Number: NCT01282333

Locations: 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸
Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy